Stephanie Sommer, PhD

No differences were observed between BI 1358894 treatment groups and placebo for primary and secondary endpoints. BI 1358894 was well tolerated with no increase in self-harm or suicidality.

Although the primary endpoint was not met, BI 1358894 was well-tolerated with no increase in self-harm or suicidality.